Despite significantly extending survival for younger adults with advanced non-small cell lung cancer, immune checkpoint inhibitors have conferred only modest OS gains over time among patients aged older than 75 years, study results showed.
The increase of slightly more than a month in median OS among older adults who received immune checkpoint inhibitors since the FDA approved their use in 2011 does not meet the definition of a clinically meaningful benefit based on ASCO guidance, the investigators noted.
Adoption of immune checkpoint inhibitors following their commercial approval occurred at